CSL buys way into cell, gene therapy

Original article by Sarah-Jane Tasker
The Australian – Page: 19 : 29-Aug-17

CSL has announced that it will spend $US91 million ($A114 million) on the purchase of US-based biotechnology company Calimmune. CSL executive Andrew Nash says the purchase of Calimmune gives it access to skills and technologies in the area of gene and cell-based therapies that it does not currently have. He said that CSL has had its eye on Calimmune, which has operations in both the US and Australia, for about a year.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s